Enlitic, a San Francisco, CA-based company utilizing artificial intelligence to streamline medical imaging workflows for radiologists, closed its $15M Series B financing round.
The round was led by Marubeni, with participation from Capitol Health and investors in Australia.
The company plans to use the funds to enhance its artificial intelligence product portfolio, expand its engineering and data scientist teams, and focus on regulatory approval for clinical use in the US, Australia, Japan, Europe, Canada, and Brazil.
Led by Kevin Lyman, CEO, and Radiologist Dr. Anthony Upton, Chief Medical Officer, Enlitic uses deep learning and other forms of artificial intelligence to develop algorithms that identify and analyze suspicious findings in medical images. Working closely with hospitals and radiology providers around the world, the company has developed a comprehensive platform enabling the development, validation, and integration of clinical AI at scale.
Enlitic’s first product interprets chest x-rays, triaging normal from abnormal scans, and detecting and characterizing more than 40 distinct abnormalities such as cardiomegaly, lung nodules, and pneumothorax.